A comparison of mycophenolate mofetil with ciclosporine for the treatment of chronic plaque-type psoriasis

Dermatology

Volumn 219, Issue 2, 2009, Pages 126-132

  Beissert, Stefan ^a,e   Pauser, Sylvia ^a   Sticherling, Michael ^b,c   Frieling, Uta ^a   Loske, Klaus Dieter ^a   Frosch, Peter J ^d   Haase, Ingo ^e   Luger, Thomas A ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d KLINIKUM DORTMUND   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Immunosuppression; Psoriasis, clinical study; T cells

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SANDIMMUN OPTORAL; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOKALEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; URIC ACID BLOOD LEVEL;

ADULT; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROBABILITY; PROSPECTIVE STUDIES; PSORIASIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 69349100682     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000226134     Document Type: Article

References (33)

1. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M: Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002; 138: 591-600. (Pubitemid 34887830)
2. Koo J: Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14: 485-496. (Pubitemid 26249398)
3. Krueger JG: The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23. (Pubitemid 34073472)
4. Schön MP, Boehncke WH: Psoriasis. N Engl J Med 2005; 352: 1899-1912.
5. Gelfand JM, Troxel AB, Lewis JD, et al: The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143: 1493-1499. (Pubitemid 350277763)
6. Schön MP: Advances in psoriasis treatment. Lancet 2005; 366: 1367-1374.
7. Weinstein GD, White GM: An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993; 28: 454-459.
8. Sabat R, Philipp S, Hoflich C, et al: Immunopathogenesis of psoriasis. Exp Dermatol 2007; 16: 779-798.
9. Schön MP: Animal models of psoriasis: a critical appraisal. Exp Dermatol 2008; 17: 703-712.
10. Berth-Jones J, Voorhees JJ: Consensus conference on cyclosporin A microemulsion for psoriasis, June 1996. Br J Dermatol 1996; 135: 775-777. (Pubitemid 26375897)
11. Flytström I, Stenberg B, Svensson A, Bergbrant IM: Methotrexate vs ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008; 158: 116-121. (Pubitemid 350221914)
12. Heydendael VM, Spuls PI, Opmeer BC, et al: Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658-665.
13. Ho VC, Griffiths CE, Albrecht G, et al: Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Br J Dermatol 1999; 141: 283-291. (Pubitemid 29397997)
14. Koo J: A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. Br J Dermatol 1998; 139: 88-95.
15. Sandhu K, Kaur I, Kumar B, Saraswat A: Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from north India. J Dermatol 2003; 30: 458-463. (Pubitemid 36829974)
16. Spuls PI, Witkamp L, Bossuyt PM, Bos JD: A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol 1997; 137: 943-949. (Pubitemid 28011136)
17. Epinette WW, Parker CM, Jones EL, Greist MC: Mycophenolic acid for psoriasis: a review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 1987; 17: 962-971. (Pubitemid 18021884)
18. Jones EL, Epinette WW, Hackney VC, Menendez L, Frost P: Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol 1975; 65: 537-542.
19. Marinari R, Fleischmajer R, Schragger AH, Rosenthal AL: Mycophenolic acid in the treatment of psoriasis: long-term administration. Arch Dermatol 1977; 113: 930-932. (Pubitemid 8146834)
20. Haufs MG, Beissert S, Grabbe S, Schütte B, Luger TA: Psoriasis vulgaris treated successfully with mycophenolate mofetil. Br J Dermatol 1998; 138: 179-181. (Pubitemid 28077960)
21. Zhou Y, Rosenthal D, Dutz J, Ho V: Mycophenolate mofetil (Cellcept) for psoriasis: a two-center, prospective, open-label clinical trial. J Cutan Med Surg 2003; 7: 193-197. (Pubitemid 36859095)
22. Fredriksson T, Pettersson U: Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244. (Pubitemid 8387357)
23. Finlay AY, Kelly SE: Psoriasis - an index of disability. Clin Exp Dermatol 1987; 12: 8-11.
24. Finlay AY, Khan GK, Luscombe DK, Salek MS: Validation of Sickness Impact Profile and Psoriasis Disability Index in psoriasis. Br J Dermatol 1990; 123: 751-756.
25. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
26. Peto R, Peto J: Asymptomatically efficient rank invariation test procedures (with discussion). J R Stat Soc A 1972; 135: 185-206.
27. Sterry W, Barker J, Boehncke WH, et al: Biological therapies in the systemic management of psoriasis: international consensus conference. Br J Dermatol 2004; 151(suppl 69):3-17. (Pubitemid 39215184)
28. Lebwohl M, Ellis C, Gottlieb A, et al: Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998; 39: 464-475. (Pubitemid 28417385)
29. Berth-Jones J, Henderson CA, Munro CS, et al: Treatment of psoriasis with intermittent short course cyclosporin (Neoral): a multicentre study. Br J Dermatol 1997; 136: 527-530. (Pubitemid 27160325)
30. Griffiths CE, Powles AV, McFadden J, Baker BS, Valdimarsson H, Fry L: Long-term cyclosporin for psoriasis. Br J Dermatol 1989; 120: 253-260.
31. Behrend M: Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001; 24: 645-663.
32. Lipsky JJ: Mycophenolate mofetil. Lancet 1996; 348: 1357-1359.
33. Davison SC, Morris-Jones R, Powles AV, Fry L: Change of treatment from cyclosporin to mycophenolate mofetil in severe psoriasis. Br J Dermatol 2000; 143: 405-407. (Pubitemid 30650413)